MedTrace Logo

Evolocumab Pregnancy Exposure Registry

NCT02957604 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2020-12-17

No results posted yet for this study

Summary

This is a prospective observational registry study to evaluate fetal, infant and childhood outcomes in women exposed to evolocumab during pregnancy

Conditions

  • Hypercholesterolemia; ASCVD; Pregnancy

Interventions

DRUG

evolocumab

Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.

Sponsors & Collaborators

  • Organization of Teratology Information Specialists (OTIS) Research Center - tel: 1-866-626-6847 or www.mothertobaby.org

    collaborator UNKNOWN

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
1 Year
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2020-09-02
Completion
2020-09-02

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02957604 on ClinicalTrials.gov